je.st
news
Clovis Oncology reports lucitanib Phase 1/2a monotherapy study results at ASCO
2014-05-31 19:24:01| Logistics - Topix.net
Clovis Oncology today announced results from an ongoing Phase 1/2a monotherapy study evaluating lucitanib, the Company's novel, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 , vascular endothelial growth factor receptors 1 through 3 and platelet-derived growth factor receptors alpha and beta .
Tags: results
study
reports
phase
Category:Transportation and Logistics